PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

GlobeNewswire Europe

REGULATED INFORMATION

GHENT, Belgium, 1 October 2013 - Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Gimv NV and Biotech Fonds Vlaanderen NV.

The above shareholders notified that they have dropped below the 5% threshold and now hold 2,208,702 Ablynx shares, which represent 4.53% of the current 48,802,115 outstanding shares of Ablynx.

Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv Life Sciences 2004 NV. Gimv NV (929,473 voting rights), Adviesbeheer Gimv Life Sciences NV (0 voting rights), Adviesbeheer Gimv Life Sciences 2004 NV (165,040 voting rights) and Biotech Fonds Vlaanderen NV (1,114,189 voting rights) are acting in mutual agreement. The Flemish Region in Belgium is the ultimate shareholder of Biotech Fonds Vlaanderen NV.

Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and six Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t:   +44 207 920 2345
e:  ablynx@consilium-comms.com

press release in pdf format



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE

HUG#1732864

Rates

View Comments (0)